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Abstract 
Skeletal muscle atrophy occurs in many pathological conditions, e.g. AIDS, cancer, 
sepsis and starvation, and with increased age. There is currently no effective treatment 
to prevent or reverse this muscle wasting. The TRPV1 agonist, capsaicin, has previously 
been shown to have a protective effect against skeletal muscle atrophy in mice as well 
as stimulate hypertrophy. We therefore investigated the effects of capsaicin against 
dexamethasone-induced atrophy in human primary skeletal muscle myotubes. By 
treating myotubes with 50μM dexamethasone we successfully induced atrophy, and saw 
a significant decrease in total protein content as well as MYH2 expression without a 
change in the atrophy genes BNIP3, GABARAPL1 and FBXO32. 100nM capsaicin 
treatment in isolation had no effect on protein content but significantly elevated the 
expression of MYH2 and MYOG above that of dexamethasone-treated cells as well as 
untreated control. However when combined with dexamethasone, capsaicin reduced 
some of the negative effects seen previously with dexamethasone alone. The addition of 
TNFα to the cell culture medium failed to induce atrophy in these myotubes. From the 
findings of this initial experiment it can be conclude that capsaicin has the capacity to 
protect against dexamethasone-induced atrophy in these human skeletal myotubes.   
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Chapter 1: Introduction  
1.1 Skeletal muscle and Atrophy 
Skeletal muscle is the largest organ of the body and serves several important functions; 
from allowing locomotion through muscle contractions to regulating metabolism. It is a 
highly responsive tissue and is capable of adaptations to altered activity, metabolic 
stimuli, and pathological condition
1
 . This includes muscle regeneration in response to 
an injury, the gaining of muscle mass in response to increased activity or growth 
stimuli, hypertrophy, or atrophy, the loss of skeletal muscle mass from lack mechanical 
stimuli during bed-rest, or in response to catabolic disease states, or aging
1,2
. Atrophy is 
the loss of skeletal muscle mass and function, through a decrease in muscle fiber size as 
a result of the loss of cytoplasm, organelles and proteins and it can result from 
malnutrition, immobilization and disuse, aging (sarcopenia) or diseases such as cancer, 
AIDS, chronic obstructive pulmonary disease (COPD) or chronic kidney disease
1,3
. 
Cancer cachexia is a type of atrophy and a complex multifactoral syndrome associated 
with cancer and is defined as the “involuntary loss of skeletal muscle mass, with or 
without the loss of fat mass, which cannot be reversed by nutritional interventions and 
leads to a severe impairment” 3,4.Increased skeletal muscle mass is strongly linked to 
success and tolerance of cancer treatments and therefore is the decrease in skeletal 
muscle mass directly linked to increased mortality and morbidity in cancer patients
5
. 
With cachexia affecting roughly 50% of all cancer patients, it is associated with ~20% 
of all cancer related deaths
6
. In refractory cachexia, the late stages of cachexia life 
expectancy is roughly three months
4,7,8
. Cachexia is also associated with anorexia, 
abnormal metabolism, negative protein balance and often, but not always systemic 
inflammation 
4,5,8,9
. The loss of skeletal muscle mass and function associated with 
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aging, sarcopenia is multifactorial like cancer cachexia but includes factors such disuse, 
chronic inflammation, malnutrition as well as altered endocrine function
10
. Sarcopenia 
has also been associated with increased risks of falls, reduced independence and as in 
other atrophic conditions, with a decreased quality of life 
7,11
. Some of the molecular 
mechanisms involved in these conditions differ, but all atrophic conditions ultimately 
stem from a disruption of the processes involved in the maintenance of skeletal muscle 
mass.  
 
1.2 The maintenance of skeletal muscle mass by protein turnover, and changes in the 
turnover during atrophy 
The maintenance of skeletal muscle mass and size is dependent on protein turnover, the 
balance between the protein degradation and the protein synthesis pathways within the 
muscle fibre. The processes involved in the degradation and synthesis of proteins are 
fluid and constantly ongoing, and altered according to the cellular needs and therefore 
allowing for the adaptation to changing conditions and stimuli
1,12
. Under normal 
conditions the cell maintains this balance between breakdown and synthesis. However 
when this balance is disrupted and either muscle protein synthesis is reduced, with no 
change in degradation rate, or the degradation of muscle proteins is increased, with or 
without a reduction in protein synthesis, atrophy occurs
2,12–14
. Many atrophy conditions 
share the same transcriptional program which leads to this change in turnover and 
negative protein balance
15
. There are two main pathways responsible for the 
degradation of proteins and organelles; the ubiquitin-proteasome pathway (UPP) and 
the autophagy pathway. Emerging evidence indicates a level of cross-talk between these 
pathways which allows for some compensation should the function of one pathway be 
10 
 
disrupted
16
. Under normal conditions these two protein degradation pathways protect 
the cell by the destruction of damaged, aged and misfolded proteins which otherwise 
could be harmful
12,17
, but these pathways also allow the cell to undergo remodelling in 
response to physiological changes by the controlled breakdown of specifically selected 
proteins
13,18
. This enables the muscle cells to adapt to changes in the physiological 
conditions and in turn, adaptation of the skeletal muscle to changes in activity. 
Misregulation and disruption of the function of these pathways can lead to inadequate 
clearance and the build-up of misfolded, damaged or otherwise harmful proteins and 
this has in turn been shown to play a role in the several myopathies and muscular 
dystrophies
12,19,20
. While the functions of these two pathways are interlinked, the direct 
processes involved in the selection of a protein for a particular pathway and the 
following degradation of the proteins differ between the two.  
The UPP use a multi-step pathway and poly-ubiquitin chains to target and remove short-
lived sarcomeric proteins by degradation by the proteasome
16,18
. The multistep pathway 
starts with the activation of ubiquitin by ubiquitin-activating enzymes (E1) in an ATP-
dependent fashion after which the activated ubiquitin is transferred to an ubiquitin-
conjugating enzyme (E2). An ubiquitin protein ligase (E3) then subsequently interacts 
with the E2 to identify the substrate and catalyses the attachment of ubiquitin to the 
target protein. Further E2-E3 interactions create a polyubiquitin chain which tags the 
protein for degradation by the proteasome. Only a protein with an attached 
polyubiquitin chain is recognised and docked onto the proteasome, which degrades the 
ubiquitinated protein into short peptides and amino acids which thereafter can be reused 
by the cell
1,21,22
. The ubiquitin tagging of selected proteins makes the proteasomal 
degradation of proteins a highly selective, but also reversible process as ubiquitin can be 
released by the deubiquiting enzymes (DUBs) although the process involved in 
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deubiquitionation are not fully understood
12,14,23
. A few ubiquitin ligases involved in 
this process have been characterized in skeletal muscles, and the two main ones are 
Muscle RING-finger protein 1 (MuRF1) and F-Box Protein 32 
(FBXO32/MAFbx1/Atrogin-1). These E3 ligases are both involved in the ubiquitination 
of skeletal muscle proteins, and have been shown to be increased during atrophy
13,14
. 
MuRF1 ubiquitinates the myosin heavy chain and myosin light chain as well myosin 
binding protein C  for UPP degradation
24
. While MuRF1 degrades myofibrillar proteins, 
FBXO32 targets the myoblast determination protein 1 (MyoD) and the eukaryotic 
translation initiation factor 3 subunit-F (eIF3-f). It has therefore been suggested that 
MuRF1 causes atrophy by directly degrading the myosin proteins and the thick 
filaments of the sarcomere. FBXO32 on the other hand has been shown to cause atrophy 
by down-regulating protein synthesis through its role as an E3 ligase for eIF3-f, and 
MyoD 
25
. Knockout mice for MuRF1 or FBXO32 display a protection against muscle 
wasting by different stimuli and both E3 ligases have been found to be regulated by the 
activation of the members of Forkhead Box, subunit O transcription factors (FOXOs) 
26
. 
By targeting myogenic factors increased FBXO32 activation leads to decrease protein 
synthesis
27
.  
 
Another muscle-specific F-box protein (FBXO40) has also been shown to negatively 
impact the protein synthesis mechanism by enhancing ubiquitination of the IRS1, 
insulin receptor substrate 1
28
. This increased proteasome-mediated degradation of IRS1 
affects the IGF-1/IRS1/PI3K/Akt protein synthesis pathway and negatively affects 
muscle mass. Knockdown of Fbxo40 in C2C12 myotubes result in hypertrophy, 
increasing myotube size by as much as 50%
28
. Young Fbxo40 null mice also display a 
similar hypertrophic phenotype, being larger and having more skeletal muscle mass 
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compared to wild type mice
28
. The activity of these ubiquitin ligases therefore not only 
regulates the protein degradation process but also in part regulate the protein synthesis 
pathways as well. These observations clearly show an involvement of the ubiquitin 
proteasome pathway in atrophy.   
The other main pathway involved in protein degradation is the autophagy-lysosome 
pathway, which controls the destruction of damaged and misfolded proteins, protein 
aggregates, as well as cytoplasm and organelles like mitochondria by delivering these to 
the lysosome
12,14,20
. Autophagy serves, just as the UPP, an important function in the 
recycling of proteins and amino acids, but also acts as a quality control mechanism of 
synthesised proteins and aids in cellular remodelling
14,18,20,21
. Because of these 
important functions in the maintenance of cellular functions, the malfunctioning of the 
autophagic system in muscle plays a large role in myopathies and malfunctioning of this 
process in other tissues than skeletal muscle has been linked to many human diseases 
such as Parkinson’s disease and cancer17,18,21. There are three types of autophagy; 
macroautophagy, microautophagy and chaperone-mediated autophagy. Macroautophagy 
is characterised by the formation of double-membrane vacuoles, autophagosomes, 
which are used for the delivery of proteins and material to the lysosome where 
degradation takes place. An autophagosome forms around a portion of the cytoplasm, 
including the protein aggregates, organelles and other materials that are to be degraded. 
Next the mature autophagosome fuses with the lysosome forming an autolysosome 
whereby the outer membrane of the autophagosome is incorporated into that of the 
lysosome and the inner autophagosome membrane is degraded together with the content 
of the vacuole
1,14
. Microautophagy on the other hand involves the direct engulfment of 
small portions of the cytoplasm by the lysosome without the formation of 
autophagosomes
20
. The third type of autophagy is chaperone-mediated autophagy, and 
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it requires the recognition of the KFERQ motif, a specific amino acid sequence, on the 
protein by the Heat shock cognate 70 (Hsc70) chaperone. The chaperone-mediated 
autophagy facilitates the degradation of damaged cytosolic proteins displaying this 
KFERQ-sequence, as the Hsc70 chaperone delivers these proteins to the lysosome via 
the lysosomal-associated membrane protein 2 (Lamp2a) receptors on the lysosomal 
membrane translocating the protein across the lysosomal membrane and into the 
organelle where it is finally degraded
1,20,29,30
. The use of ubiquitin molecules to tag 
proteins for degradation is also used by the autophagy-lysosome pathway and these are 
the mono-ubiquitinated proteins, and not the poly-ubiquitinated proteins targeted by the 
ubiquitin-proteasome pathway. When recognised, these mono-ubiquitin tagged proteins 
are then degraded by the lysosome. However further research is needed to fully 
elucidate the exact mechanisms involved in the recognition of these proteins by the 
lysosome and the selectivity for a particular pathway 
13,14,30
. This however highlights 
some overlap in the processes involved in these two protein degradation pathways. 
Because of its role in maintaining cellular function the autophagy-lysosome pathway is 
present at low levels under normal conditions maintaining muscle cell function, but is 
further activated in atrophy conditions
14
. Autophagy genes like microtubule-associated 
protein 1 light chain 3 (LC3), BCL2/adenovirus E1B 19kDa protein-interacting protein 
3 (BNIP3) and gamma-aminobutyric acid receptor-associated protein-like 1 
(GABARAPL1) are all up-regulated in atrophy
30
. LC3 and GABARAPL1 play an 
important role in the formation of the autophagosome membranes and the fusion with 
the lysosome and BNIP3 is one of the key regulators of mitochondrial degradation and 
biogenesis
31
. The activation of FOXOs has been shown to be necessary for the 
activation of these autophagy genes and for their role in atrophy. Inhibition of FOXO 
activity has been shown to prevent skeletal muscle atrophy and the up-regulation of 
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these genes
31–33
. Therefore the actions of LC3, GABARAPL1 and BNIP3 are under 
FOXO control just as MuRF1 and FBXO32
13,31–33
. FOXOs therefore control both of the 
protein degradation pathways and regulate the increased degradation seen in atrophic 
conditions, but also regulate the rate of protein synthesis through the Akt/mTOR 
pathway.  
 
Protein synthesis is stimulated by feeding and skeletal muscle activity
34
. The main 
pathway of protein synthesis, and hypertrophy, is the insulin-like growth factor 1 (IGF-
1)/ Akt/ mammalian target of rapamycin (mTOR) pathway. This signalling is mediated 
through the binding of IGF-1 to its plasma membrane receptor, the IGF1 receptor 
(IGF1R) and the resulting phosphorylation leads to the recruitment and interaction with 
IRS1 (insulin receptor substrate 1). The phosphorylation of IRS1 in turn leads to the 
down-stream phosphorylation of phosphatidylinositol-4, 5-bisphosphate 3-kinase 
(PI3K), plasma membrane intrinsic protein 3 (PIP3) and the subsequent activation of 
Akt. Akt is a regulator of protein synthesis as it regulates the activity of the mammalian 
target of rapamycin (mTOR)
35
. mTOR exists as two complexes 1 and 2, mTORC1 and 
mTORC2, mTORC1 associates with RAPTOR and is inhibited by rapamycin. 
mTORC2 associates with RICTOR and upon activation acts as a positive feedback loop 
further stimulating the activation of Akt
34,35
. mTORC1 on the other hand is responsible 
for the activation of ribosomal protein S6 kinase, 70kDa, polypeptide 1 (p70S6K) and 
the eukaryotic translation initiation factor 4G (eIF4G) as well as the inhibition of the 
eukaryotic translation initiation factor 4E binding protein 1(4E-BP1)
13,36
. The inhibition 
of 4E-BP1 allows for the formation of the eukaryotic translation initiation factor 4F 
(eIF4F) complex which is required for the initiation of translation. The eIF4F complex 
is formed by the dissociation of eukaryotic translation initiation factor 4E (eIF4E) from 
15 
 
4E-BP1 and its subsequent binding to the phosphorylated eIF4G and eukaryotic 
translation initiation factor 4A (eIF4A), enabling the start of protein synthesis
25,34,37
. 
The activation of p70S6K and its downstream target ribosomal protein S6 regulates 
protein translation  and leads to protein synthesis 
13,25,37
. Akt not only stimulates protein 
synthesis through the activation of mTORC1, it also drives translation and protein 
synthesis by inhibiting GSK3β, thereby allowing the promotion of translation by the 
activity of eIF2B 
13,25,34
.  
 
In addition to its role in the regulation of protein synthesis Akt also functions as an 
inhibitor of FOXOs and thereby regulates the protein degradation pathways
32,38
. Akt 
suppress the activity of the FOXO transcription factors preventing the transcription of 
MuRF1, FBXO32, BNIP3, GABARAPL1 and LC3, down-regulating both the 
ubiquitin-proteasome pathway and autophagy 
14,32,38
. Latres et al (2005) showed that the 
atrophy in C2C12 myotubes induced by dexamethasone supplementation was reversed 
with the activation of the Akt/mTOR pathway by IGF-1 further supporting the role of 
the IGF-1/Akt/mTOR pathway in both protein synthesis and degradation. The inhibition 
of FOXO in mice and C2C12 myotubes also resulted in prevention of atrophy when 
models of Lewis lung carcinoma and sepsis were used
32
. In addition the knockout of 
S6K1, one of the downstream targets of the Akt/mTOR pathway, in myotubes resulted 
in an atrophy response emphasising the role of this pathway in the control of skeletal 
muscle protein turnover
39
.  
 
In summary the increased activation of the IGF-1/Akt/mTOR pathway leads to 
increased protein synthesis and increased skeletal muscle growth and hypertrophy in 
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skeletal muscle. The interplay between the levels of synthesis and degradation governs 
protein turnover and these processes also regulate each other. Protein synthesis has been 
shown to be suppressed in atrophy
40–43
 while the protein degradation pathways are up-
regulated 
1,24,25,44
.  
 
1.3 The role of glucocorticoids and pro-inflammatory cytokines in atrophy 
Glucocorticoids like dexamethasone have been frequently used to induce atrophy in 
rodents and cell culture. Excessive levels of glucocorticoids in patients suffering from 
Cushing’s syndrome and in patients receiving glucocorticoid treatments cause skeletal 
muscle atrophy
15,45,46
. Dexamethasone treatments have been shown to induce skeletal 
muscle atrophy, reducing skeletal muscle mass, myofibre size, mitochondrial content 
and function in rodents and rodent cell lines
19,27,38,47–49
. Dexamethasone causes skeletal 
muscle atrophy by increasing protein degradation in combination with a down-
regulation of protein synthesis. The activation of the glucocorticoid receptor (GR) in the 
plasma membrane by dexamethasone stimulates the up-regulation of regulated in 
development and DNA damage responses 1 (REDD1) and the transcription factor 
kruppel-like factor-15 (KLF-15)
48,50,51
. REDD1 is an mTOR inhibitor and while KLF-
15 also blocks mTOR activation, more importantly it directly stimulates the expression 
of FBXO32 and the activation of FOXOs 
25,52–54
. The inhibition or deletion of REDD1 
in rodents or in L6 rat cells have been shown to prevent dexamethasone-induced 
atrophy 
53–55
 suggesting that the inhibition of protein synthesis might play an even more 
important role than the increased degradation in this form of atrophy. The activity of the 
GR therefore prevents skeletal muscle protein synthesis by the inhibition of mTOR 
17 
 
activity, and leads to an increased rate of degradation through the activity of both the 
ubiquitin-proteasome E3 ligases and autophagy.  
 
Increased levels of pro-inflammatory cytokines have also been implicated in the 
induction of atrophy in cancer cachexia, sepsis and other wasting conditions
25,56
. The 
cytokine tumour necrosis factor-α (TNF-α) has been shown to be a useful marker for 
malnutrition in patients with gastric cancer
57
 and to induce atrophy in cultured C2C12 
myotubes
58
. TNF-α also inhibits myotube formation when administered to cultured 
human primary cells
59,60
 and have been shown to up-regulate the expression of MuRF1 
and FBXO32 via p38 mitogen-activated protein kinase (MAPK) and the nuclear factor 
of kappa light polypeptide gene enhancer in B-cells (NF-KB) pathway
14,56
.  NF-KB and 
p38 MAPK therefore drives atrophy through the increased degradation of proteins via 
the ubiquitin-proteasome pathway and targeted destruction of myosin heavy chain, 
myosin light chain and MyoD and eIF3-f by the increased expression of MuRF1 and 
FBXO32 as mentioned previously
14,25,56
.  
 
1.4 Capsaicin and the activation of TRPV1 as a potential treatment of muscle wasting  
The pathways discussed above makes it clear that the changes in protein turnover 
associated with atrophy in wasting conditions are complex, and while the knowledge 
about the processes and pathways involved are growing, few interventions to date have 
been successful and there is currently no effective treatment to prevent or reverse this 
muscle wasting. However emerging evidence from rodent studies points towards a 
compound present in chilli peppers which seems to induce hypertrophy and protect 
against atrophy in mice through increased intracellular calcium levels [Ca
2+
]i. 
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Capsaicin, the transient receptor potential cation channel, subfamily V member 1 
(TRPV1) agonist and the compound that gives chilli peppers their strong hot flavour, 
have been shown to have a protective effect against skeletal muscle atrophy in mice as 
well as regulate hypertrophy
61,62
. Ito et al (2013) found that neuronal nitric oxide 
synthase (nNOS) regulated overload-induced hypertrophy in mice by the production of 
nitric oxide and peroxynitrite leading to the activation the TRPV1, using a synergist 
ablation method where the plantaris muscle is forced to adapt and compensate for the 
gastrocnemius and soleus muscles after the ablation of the tendons to these synergistic 
muscles. Activation of the TRPV1 led to the release of [Ca
2+
]i from the sarcoplasmic 
reticulum activating mTOR and stimulating skeletal muscle hypertrophy in these mice. 
Interestingly, when TRPV1 was activated by the administration of its agonist capsaicin, 
the effect on mTOR and p70S6K protein levels and phosphorylation was equivalent to 
the effects seen with overload. These changes were not seen in the TRPV1 null mice, 
suggesting that this hypertrophy response is indeed regulated by TRPV1 activation in 
mice skeletal muscle. They also found that mice receiving daily capsaicin 
supplementation resulted in increased mass of the soleus, plantaris and the 
gastrocnemius muscles, and increase in myofibre size, as well as increased muscle force 
production in the extensor digitorum longus (EDL) muscle, compared to mice who did 
not receive the supplement
61
. Leading on from these findings they investigated the 
potential for capsaicin-stimulated activation of TRPV1 to influence skeletal muscle 
during disuse atrophy. Interestingly mice supplemented with capsaicin during hindlimb 
suspension lost significantly less of the soleus and gastrocnemius muscles compared to 
control, and denervation resulted in a significantly larger loss of mass of the 
gastrocnemius muscle in control mice compared to the mice receiving the capsaicin 
treatment
61
. 
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In another study following up on these results, the same group found that TRPV1 
activation by capsaicin supplementation in mice resulted in increased phosphorylation 
of p70S6K and S6 without inducing phosphorylation of Akt, with similar changes being 
seen within 3 minutes of mechanical overload
62
. The findings from these studies suggest 
that capsaicin has the potential to induce skeletal muscle hypertrophy in a similar 
manner to resistance exercise and the potential to protect skeletal muscle mass from 
atrophy through the TRPV1-mediated increased levels of [Ca
2+
]i
61,62
.   
 
1.5 The problems involved with cell culture and rodent models of atrophy 
As the majority of the research on atrophy have been conducted using rodent in vitro 
and in vivo models, with limited research being conducted using human cell culture or 
in clinical populations the evidence for the exact mechanisms taking place in humans 
during states of atrophy are not clearly understood. Similarly the research highlighted 
above suggesting that capsaicin acts as a resistance exercise mimic and has potential to 
protect against atrophy during denervation and hindlimb suspension needs further 
validating in human model systems before its role as a treatment against muscle wasting 
can be asserted. In addition previous research have shown that there are some slight 
differences in the response to dexamethasone when used as an atrophy-inducer in 
C2C12 mice skeletal muscle myotubes and L6 rat skeletal muscle myotubes
49
. Also, 
Owens et al (2013) reported differences in differentiation capacity of myoblasts and the 
response to treatment in myotubes, when human primary skeletal muscle cells obtained 
from different vendors were compared
63
.   
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1.6 Aims and Objectives  
In response to the issues highlighted above in section 1.5 the first aim of the present 
study was to investigate the differentiation capacity of the human primary skeletal 
muscle cells used and repeat the characterization of the gene expression during 
differentiation performed by Owens et al (2013) to locate the optimal time point during 
differentiation at which to perform our experiments. Secondly this study sought to 
investigate the effects of dexamethasone, TNF-α and capsaicin on these human skeletal 
muscle myotubes when administered to the culture in isolation to: i) investigate the 
effects of dexamethasone on these human skeletal muscle myotubes and validate the use 
of this glucocorticoid as a method to induce atrophy based on the findings of Owens et 
al, ii) to explore the suggested potential for capsaicin to induce hypertrophy in skeletal 
muscle using this human cell culture model, iii) also validate the use of TNF-α an 
atrophy-inducer in these cells as previous research indicates a role for TNF-α in 
atrophy, and iv) measure the potential changes in gene expression in response to these 
treatments. Lastly this study also aimed to further investigate and elucidate the potential 
for capsaicin to protect against dexamethasone-induced skeletal muscle atrophy.  
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Chapter 2: Materials and Methods 
2.1 Cells culture  
Human skeletal muscle myoblasts were purchased from Lonza (Clonetics® HSMM, 
Cat# CC-2580 Lot# 0000257384, Walkersville, USA). The cells were harvested from 
the quadriceps muscle of a non-diabetic 17 year old female donor.  The myoblasts were 
cultured at 37⁰C with 5% CO2, in growth medium (GM) consisting of Skeletal Muscle 
Cell Basal Medium  without L-Glutamine (Clonetics®) supplemented with  
dexamethasone, Epidermal Growth Factor (EGF), 10% fetal calf serum, 2% L-
Glutamine, gentamicin and amphoteracin. The cells were cultured to ~50-70% 
confluence. Prior to experiments cells were collected using Trypsin-EDTA (Gibco®) 
and counted using the TC20
TM
 automated cell counter (Bio-Rad Laboratories Inc.). To 
induce differentiation and start the experimental treatments cells were seeded in 6-well 
or 12-well polystyrene cell culture plates at various densities depending on the 
experiment and incubated overnight in GM. Differentiation was induced by transfer to 
differentiation medium (DM) consisting of Dulbecco’s Modified Eagle Medium (2% 
horse serum, amphoteracin (250μg/ml) and gentamicin (10mg/ml) all from Life 
Technologies) following the recommendations by Lonza. Myoblasts were differentiated 
over 5-7 days with medium changed every 48 hours. Treatments were added to DM on 
day 3 or 5 when myotube formation was apparent microscopically.   
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2.2 Experimental design and treatments: The gene expression profile of 
differentiation 
To investigate the gene expression profile of the human skeletal muscle myoblasts 
during the course of differentiation cells were seeded in 6 wells on four separate 12-well 
cell culture plates at ~5.2x104 cells per cm2 and incubated in GM overnight. The 
following morning (Day 0) three wells from each plate were harvested into QIAzol® 
Reagent (Qiagen) and stored at -80⁰C for later analysis. The remaining cells were 
washed and DM added to the wells. Cells in DM were harvested at days 1, 3, 5 and 7 of 
differentiation into QIAzol reagent and stored at -80⁰C.  
 
2.3 Experimental design and treatments: The effects of dexamethasone and capsaicin 
in isolation  
Myoblasts were seeded at a density of ~1x10
3
 cells per cm
2
 in 6-well polystyrene cell 
culture plates. After 24 hours in GM cells were differentiated as above. On day 5 of 
differentiation DM was supplemented with either 50μM dexamethasone (Merck) or 
100nM capsaicin (Merck), or with vehicle (DMSO) only. After 72 hours cells were 
harvested as above and stored at -80⁰C for later analysis.  
 
2.4 Experimental design and treatments: The combined effects of dexamethasone and 
capsaicin and optimization of the capsaicin concentration 
Myoblasts were seeded at 3.2x10
4
cells per cm
2
 in 6-well plates in GM for 48 hours 
before being replaced with DM. After 72 hours the medium was changed to DM with 
DMSO (vehicle) or supplemented with dexamethasone at 50μM in DMSO, or a 
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combined treatment: 50μM dexamethasone plus capsaicin at 100nM, 1 μM, 10μM or 
100μM all in DMSO. After a further 48 hours myotubes were harvested into QIAzol 
and frozen at -80⁰C for further analysis.      
 
2.5 Experimental design and treatments: Investigating TNF-α induction of atrophy 
Myoblasts were seeded at a density of 3.2x10
4
cells per cm
2 
in 6-well plates in GM for 
48 hours before being replaced with DM. After 72 hours DM was supplemented with 
TNF-α (Merck) at 10ng/ml, 20ng/ml or 40ng/ml in H2O. After a further 48 hours cells 
were harvested as detailed above.  
 
2.6 Fluorescence Microscopy   
Cells were seeded in 6-well cell culture plate at ~2.1x10
4
 cells per cm
2
 and after 48 
hours in GM nuclei were stained with 2.5μg/ml Hoechst 33342 dye (Invitrogen). 
Myotube nuclei, originally seeded at ~5.3x10
4
 cells per cm
2
 in GM, were stained with 
2.5μg/ml Hoechst 33342 after 5 days in DM, and mitochondria were stained with 
200nM MitoTracker Green (Life Technologies). Images were then obtained using a 
Zeiss Axiovert 135 microscope and Moticam Pro252B camera, and further processed 
using ImageJ (NIH) software.  
 
2.7 RNA, DNA and Protein Isolation 
RNA was extracted from the frozen cells by the addition of 200μl chloroform to the 
lysed cells in QIAzol. After a short incubation at room temperature the mixture was 
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spun at 12000g for 15 minutes. The upper aqueous phase was removed and the 
remainder set aside for DNA and protein extraction. 500μl isopropanol was added to the 
aqueous phase and incubated in room temperature for 30 minutes, after which the 
mixture was centrifuged at 12000g for 15 minutes to pellet the RNA. The pellet was 
washed in 75% ethanol, collected by centrifugation (7500g, 5 minutes) and air dried for 
5 minutes at room temperature before being resuspended in 20μl RNAse free water. 
After RNA extraction DNA was isolated as follows. 300μl of 100% ethanol was added 
to residual material after RNA extraction. Samples were mixed by inversion, briefly 
incubated at room temperature and spun at 2000g for 5 minutes at 4
o
C. The resulting 
supernatant (containing protein) was set aside at -80
o
C. The DNA pellet was washed 
twice with 0.1M sodium citrate in 10% ethanol and then re-suspended in 1.5ml 75% 
ethanol. After a final spin at 2000g for 5 minutes the pellet was air dried and dissolved 
in 100μl 8mM NaOH. Insoluble material was removed by centrifugation at 12000g for 
10 minutes. Protein was extracted from the remaining material by precipitation with 
1.5ml isopropanol. After a 10 minute room temperature incubation protein was pelleted 
by centrifugation at 12000g for 10 minutes at 4
o
C. The pellet was washed three times in 
2ml 0.3M guanidine hydrochloride in 95% ethanol with a final wash in 2 ml 100% 
ethanol, with a 20 minutes incubation followed by centrifugation at 7500g for 5 minutes 
at 4
o
C in between each wash. The protein pellet was collected by centrifugation at 
7500g for 5 minutes and air dried for 20 minutes. The protein was re-dissolved in 150μl 
1% SDS at 50
o
C. Insoluble material was removed by centrifugation at 10000g for 10 
minutes.  DNA and RNA were measured using the Nanodrop 2000 (Thermo Scientific). 
Protein content was measured using the Biorad DC Protein assay (BioRad) with a 
standard curve prepared from bovine serum albumin ranging from 250μg/ml to 
15.625μg/ml.  
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2.8 Gene Expression Analysis: qPCR  
First strand cDNA was synthesised using the RevertAid First Strand synthesis kit 
(Thermo-Fisher) and oligo dT primers following the manufacturer’s directions. 1μg of 
RNA was the input for each reaction. After mixing the kit components and RNA the 
reaction was heated at 42
o
C for 60 minutes and then 70
o
C for 10 minutes. First strand 
DNA was stored at -20
o
C before further use. 
qPCR was carried out using the Luminaris SYBR Green High ROX qPCR Master mix 
kit (Thermo-Fisher). The kit contents and cDNA were mixed according to the 
manufacturer’s directions. Final primer concentration was 300nM for forward and 
reverse primers. Primer sequences used are shown in table 1. The PCR conditions were 
50
o
C for 2 minutes (UDG treatment), 95
o
C for 10 minutes (DNA denaturation) followed 
by 40 cycles of 95
o
C for 15 seconds and 60
o
C for 60 seconds using the LightCycler 480 
instrument (Roche). Primer efficiencies were calculated and are shown in table 2, and 
the raw qPCR data were analysed using the 2-delta-delta Ct method (Livak and 
Schmittgen, 2001). For all conditions, the gene expression levels were normalised to the 
expression of hypoxanthine phosphoribosyltransferase 1 (HPRT1). The expression of 
the structural proteins myosin heavy chain-2 (MYH2) and troponin T type1 (TNNT1), 
the transcription factors myogenin (MYOG) and myoblast determination protein 1 
(MYOD1), as well as three genes involved in skeletal muscle remodelling: 
BCL2/adenovirus E1B 19kDa protein-interacting protein 3 (BNIP3), gamma-
aminobutyric acid receptor-associated protein-like 1 (GABARAPL1) and F-box only 
protein 32 (FBXO32) were all measured by qPCR. All gene expression data were 
normalised and inverted, and are displayed in arbitrary units (AU). 
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Table 1. Forward and reverse primer sequences used for the qPCR analysis in this study. 
Forward Primers Reverse Primers 
HPRT 
5’-GCCAGACTTTGTTGGATTTG-3’ 
HPRT 
5’-CTCTCATCTTAGGCTTTGTATTTTG-3’ 
BNIP3 
5’-AACACGAGCGTCATGAAGAAAGGG-3’ 
BNIP3 
5’-ATCCGATGGCCAGCAAATGAGAGA-3’ 
FBXO32 
5’-GCCTTTGTGCCTACAACTGAA-3’ 
FBXO32 
5’-CTGCCCTTTGTCTGACAGAAT-3’ 
GABARAPL1 
5’-CCACCGCAAGGAGACAGAAG-3’ 
GABARAPL1 
5’-GAAAATGTGATGACGGTGTGT-3’ 
MYOG 
5’-GCTGTGAGAGCTGCATTCG-3’ 
MYOG 
5’-CAGTGCCATCCAGTACATCH-3’ 
MYOD1 
5’-CGCCATCCGCTATATCGAGG-3’ 
MYOD1 
5’-CTGTAGTCCATCATGCCGTCG-3’ 
MYH2 
5’-AGAAACTTCGCATGGACCTAGA-3’ 
MYH2 
5’-CCAAGTGCCTGTTCATCTTCA-3’ 
TNNT1 
5’-TGATCCCGCCAAAGATCCC-3’ 
TNNT1 
5’-TCTTCCGCTGCTCGAAATGTA-3’ 
 
 
Table 2. The calculated primer efficiencies for the primers used for the qPCR analysis in this study.  
Gene Primer efficiency 
HPRT 1.04 
BNIP3 1.18 
FBXO32 1.02 
GABARAPL1 1.02 
MYOG 1.19 
MYOD1 1.03 
MYH2 1.06 
TNNT1 1.11 
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2.9 Statistical Analysis 
All analysis was performed using Minitab
®
 17 Statistical Software (Minitab Inc.) and 
comparisons between groups were made using the One-Way ANOVA and Tukey’s 
post-hoc analysis. Comparisons were considered significant when p<0.05. The gene 
expressions were normalised to the control group and displayed in the graphs below.  
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Chapter 3: Results 
3.1 Characterisation of the human skeletal muscle myoblasts and differentiation into 
myotubes using fluorescence microscopy 
Fluorescence microscopy was performed on myoblasts and differentiated myotubes as 
an additional measure to the gene expression analysis below to characterise the 
differentiation process. Figure 1 highlights the effects of the differentiation medium; by 
day 5 after the growth medium was exchanged for differentiation medium myoblasts 
have fused and formed multinucleated myotubes. There is a clear visual increase in 
stained, blue, nuclei after differentiation and these have aligned and fused into 
multinucleated myotubes (Fig.1A-B).   
We also showed that it is possible to stain the mitochondria of these cells after 
differentiation using MitoTracker Green (Fig.1C). As atrophy is known to affect 
mitochondrial structures, number and function, this could be used to assess 
mitochondrial content and investigate the effects of dexamethasone and capsaicin on 
mitochondrial biogenesis.  
 
Figure 1. Microscopic images of the HSMM cells before and after induction of differentiation. A) 
Myoblasts kept in growth medium stained with Hoechst 33342 nuclei stain, nuclei in blue. B) Myotubes 
on day 5 of differentiation after the growth medium was exchanged for differentiation medium, nuclei 
stained blue using Hoechst 33342. C) Myotubes on day 5 of differentiation with nuclei stained blue using 
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Hoechst 33342 and mitochondria stained green using MitoTracker Green. All images taken using x20 
magnification.  
 
3.2 Characterisation of the gene expression profile of differentiation 
We first examined the gene expression profiles of myogenic genes (MYOD1, MYOG 
and MYH2) across differentiation. Expression levels for these genes were measured at 
five different time points; before differentiation (GM) and at days 1, 3, 5 and 7 after the 
addition of differentiation medium (DM) (Fig. 2). 
The expression of MYOD1 was not altered over the course of differentiation (Fig. 2a). 
There was however a significant increase in the expression of MYOG (Fig. 2b) from 
day 3 of differentiation and expression levels on day 5  were significantly higher than 
those of GM and day 1, yet this was not significantly different from day 3 and day 7. A 
similar response was seen for the expression of MYH2 (Fig. 2c) with a significant 
increase in expression from day 3 and onwards after the induction of differentiation 
compared to GM (p=0.001).  
 
Figure 2. The expression of (a) MYOD1, (b) MYOG, and (c) MYH2 were measured before and over a 7 
day period after differentiation. Conditions marked with different letters are significantly different from 
each other (p<0.05).  GM= Cells in growth medium before differentiation, DM1= Cells on day 1 after 
medium was changed to differentiation medium (DM), DM3= Day three of differentiation, DM5= Day 
five of differentiation, DM7= Day seven of differentiation.   
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These results gave us an indication of the ideal time point during differentiation to 
examine the effects of dexamethasone and capsaicin individually on the myotubes. As 
the largest differences in gene expression compared to pre-differentiation levels were 
seen after day 3 of differentiation, day 3-5 were chosen as the time point at which the 
treatments were to be added. Microscopic examination of myotube formation ultimately 
finalised the exact time point for each of the experiments as differentiation was slower 
in cells cultures with a higher passage number and lower seeding density.  
 
3.3 Characterisation of the gene expression response to Dexamethasone and 
Capsaicin 
After 5 days of differentiation, when myotubes were apparent, the DM culture medium 
was treated with DMSO only, dexamethasone (50μM) in DMSO or capsaicin (100nM) 
in DMSO. The cells were harvested after a further 72 hours in their respective 
treatment. We examined the expression of myogenic and remodelling genes and also 
assessed the changes in DNA and protein content as well as the protein:DNA ratio as an 
indicator of myotube protein turnover.  
                
 
Figure 3. The (a) DNA and (b) protein quantities and (c) Protein:DNA ratio of the cells measured under 
the three conditions, DM= Control cells in differentiation medium+ DMSO, DEX= dexamethasone 
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treated cells, Cap= cells treated with 100nM capsaicin for 72 hours. Conditions that do not share a letter 
are significantly different from each other (p<0.05).  
 
As shown in figure 3a the dexamethasone treatment significantly increased the DNA 
content compared to untreated (DMSO only) control cells (p=0.019) and to that of the 
cells receiving the capsaicin treatment (p=0.008). On the other hand the dexamethasone 
treatment significantly lowered the measured quantity of protein compared to that seen 
in the untreated control cells (p=0.001) and the capsaicin treated cells (p=0.015) 
(fig.3b). The protein:DNA ratio displayed the same pattern (fig.3c), with 
dexamethasone treatment resulting in significantly lower ratio compared to the 
untreated control cells (p=0.001) and cells receiving the capsaicin treatment (p=0.007). 
Capsaicin on the other hand did not significantly affect DNA and protein content 
compared to the DM cells nor did it affect the protein:DNA ratio. This shows that the 
capsaicin treatment had no adverse effects on myotube DNA and protein content during 
differentiation but a 50μM concentration of dexamethasone induced atrophy.  
To examine whether the treatments had any effect on gene expression during 
differentiation we examined the expression of the structural proteins MYH2 and 
TNNT1 (Fig. 4), the myogenic transcription factors MYOG and MYOD1 (Fig. 5), as 
well as three genes linked to skeletal muscle remodelling BNIP3, GABARAPL1 and 
FBXO32 (Fig. 6).  
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Figure 4. The relative gene expression of (a) MYH2 and (b) TNNT1 for each of the three conditions, 
DM=Untreated control cells (DMSO only), DEX=dexamethasone treated cells, Cap= cells treated with 
100nM capsaicin.  Conditions that do not share a letter are significantly different from each other 
(p<0.05).   
 
As seen in Fig. 4a the expression of MYH2 was significantly elevated in the cells which 
received the 100nM capsaicin treatment both compared to the control cells (p=0.001) 
and the cells treated with dexamethasone (p=0.001). Although the mean MYH2 level 
was lower in the dexamethasone treated cells than the controls this did not reach 
statistical significance. Dexamethasone treatments significantly increased the 
expression of TNNT1 above that of the untreated control cells (p=0.043) but there was 
no significant change in expression with capsaicin treatment compared to the other two 
groups.  
 
Next we measured effect of the treatments on the gene expression for the transcription 
factors MYOD1 and MYOG (Fig. 5). Dexamethasone treatment significantly increased 
the expression of MYOD1 compared to the cells in differentiation medium (p=0.001) 
and compared to the capsaicin condition (p=0.032). There was also a trend for increased 
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expression of MYOD1 with capsaicin treatment compared to control cells (p=0.05). For 
MYOG, capsaicin treatment significantly elevated the expression above that of both 
untreated control (p=0.004) and dexamethasone treated cells (p=0.007) (Fig. 5b). 
Expression in the dexamethasone treated group did not differ from that of the untreated 
control cells.   
  
 
Figure 5. The relative gene expression of the transcription factors (a) MYOD1 and (b) MYOG for each of 
the three conditions. Conditions that do not share a letter are significantly different from each other 
(p<0.05).   
 
Neither capsaicin nor dexamethasone treatment had any effect on the expression of the 
remodelling genes BNIP3 and FBXO32 (Fig. 6a, c), however capsaicin significantly 
elevated the expression of GABARAPL1 compared to both untreated control (p=0.002) 
and dexamethasone (p=0.023) (Fig. 6b). The dexamethasone treatment did not induce in 
any changes in GABARAPL1 expression compared to control cells.  
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Figure 6. The expression of the three remodelling genes (a) BNIP3, (b) GABARAPL1 and (c) FBXO32 
for each of the three conditions. Conditions that do not share a letter are significantly different from each 
other (p<0.05). 
 
3.4 Optimisation of Capsaicin concentration and the combined effect of 
Dexamethasone and Capsaicin on gene expression  
From these results using the 100nM capsaicin solution we learned that this 
concentration was a well tolerated by the cells and induced measurable changes in the 
gene expression of the skeletal muscle myotubes without negatively affecting the 
cellular protein content. In order to test whether capsaicin was capable of reversing the 
loss in protein seen in dexamethasone induced atrophy we designed a dose response 
experiment. After 3 days in differentiation medium, cells were left untreated (DM+ 
DMSO only) or treated with dexamethasone only at 50μM or dexamethasone at 50μM 
plus capsaicin at 100nM, 1μM, 10μM or 100μM all in DMSO. Results for the 
protein:DNA ratio analysis are shown in figure 7.  
 
While none of the capsaicin concentrations altered the protein content (fig.7b) and 
protein:DNA ratio (fig.7c) compared to that found in the untreated cells, both the ratio 
and the protein content of the cells treated with dexamethasone and 100nM capsaicin 
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was significantly higher than that of the cells treated with dexamethasone-only (protein 
content p=0.044, ratio p=0.008) (Fig. 7). Conversely the dexamethasone only treatment 
resulted in a small non-significant reduction in protein content and protein:DNA ratio 
compared to control. At capsaicin concentrations greater than 100nM there was no 
effect of the combined dexamethasone-capsaicin treatments compared to 
dexamethasone alone. DNA content was not changed with any of the treatments used 
(fig. 7a).   
 
Figure 7. The (a) DNA and (b) protein quantities and (c) Protein:DNA ratio of the cells measured under 
the six conditions of the dose-response experiment, DM= Untreated control, DEX= 50μM dexamethasone 
only, DEX+Cap100nM= 50μM dexamethasone and 100nM capsaicin, DEX+Cap1μM=50μM 
dexamethasone and 1μM capsaicin, DEX+Cap10μM= 50μM dexamethasone and 10μM capsaicin, 
DEX+Cap100μM= 50μM dexamethasone and 100μM capsaicin . Conditions that do not share a letter are 
significantly different from each other (p<0.05).  
 
In addition while no significant changes to the quantity of DNA and protein, and to the 
protein:DNA ratio were seen with the 100μM treatment, these cells underwent a gross 
phenotypic change and detached from the polystyrene tissue culture wells (not shown). 
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 From the protein content measurement we concluded that the 100nM concentration of 
capsaicin was the most effective concentration for relieving dexamethasone induced 
myotube atrophy and we repeated the above experiment using only 100nM capsaicin in 
combination with dexamethasone to profile gene expression changes. Thus we 
measured the expression of MYH2, TNNT1, MYOG, MYOD1, BNIP3, GABARAPL1 
and FBXO32 in untreated myotubes or myotubes treated with 50μM dexamethasone or 
50μM dexamethasone+100nM capsaicin (Fig. 8-10).  
    
 
Figure 8. The expression of (a) MYH2 and (b) TNNT1 for the three conditions, DM=Untreated control 
cells, Dex=dexamethasone treated cells, Dex+Cap= cells treated with 50μM dexamethasone and 100nM 
capsaicin. Conditions that do not share a letter are significantly different from each other (p<0.05).  
The expression of MYH2 was dramatically decreased with the dexamethasone 
treatment as seen in figure 8a (p=0.001). There was a slight rise in MYH2 expression 
when dexamethasone and capsaicin were combined but this was not significant. There 
were no effects of treatment on TNNT1 expression.  
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MYOD1 expression (Fig. 9a) was significantly increased above the levels of the control 
cells with dexamethasone treatment (p=0.002), and although the combined treatment 
seemed to inhibit that increase the difference did not reach statistical significance. There 
was no effect on MYOG expression (Fig. 9b). 
 
 
 
Figure 9. The expression of the myogenic transcription factors (a) MYOD1 and (b) MYOG from the three 
treatments, DM= untreated control cells, Dex=dexamethasone treated cells, Dex+Cap= cells treated with 
50μM dexamethasone and 100nM capsaicin. Conditions that do not share a letter are significantly 
different from each other (p=<0.05).  
 
The expression of the remodelling genes BNIP3, GABARAPL1 and FBXO32 for each 
of the conditions are shown in figure 10. Neither the dexamethasone treatment alone nor 
the combined dexamethasone+100nM capsaicin affected the expression of these genes.  
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Figure 10. The expression of the remodelling genes (a) BNIP3, (b) GABARAPL1 and (c) FBXO32 for 
the three conditions, DM= untreated control cells, Dex=dexamethasone treated cells, Dex+Cap= cells 
treated with 50μM dexamethasone and 100nM capsaicin.  
 
3.5 Validation of TNF-α as an inducer of atrophy in human primary cells   
 
Figure 11. The (a) DNA and (b) protein quantities and (c) Protein:DNA ratio measured for the untreated 
control and the cells treated with the three different concentrations of TNF-α (TNF-alpha10 = 10 ng/ml, 
TNF-alpha20= 20ng/ml and TNF-alpha40= 40 ng/ml). Conditions that do not share a letter are 
significantly different from each other (p<0.05).  
 
Lastly we wanted to do a similar dose response experiment for TNF-α as this cytokine 
has previously been used to induce atrophy in other in vitro skeletal muscle models. We 
first used a concentration of 5ng/ml of TNF-α (data not shown) and found no effect on 
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protein content or expression of the genes investigated. We therefore wanted to explore 
the effects of higher concentrations of TNF-α on the human skeletal muscle myotubes. 
The concentrations chosen were 10ng/ml, 20ng/ml and 40ng/ml of TNF-α, and the 
protein content for each concentration is displayed in figure 11.  
 
As shown in figure 11a the different doses of TNF-α had no effect on the DNA content 
compared to the untreated control cells, however there was a significant increase with 
the 40ng/ml concentration compared to the lower 10ng/ml TNF-α concentration 
(p=0.027). Protein content (fig.11b) and protein:DNA ratio (fig.11c) in these human 
cells were not changed in response to any of these TNF-α treatments. While there is a 
small downward trend with increasing concentration there were no significant 
differences between any of the treatment conditions.  
 
Figure 12. The expression of (a) MYH2 and (b) TNNT1. DM= untreated control, TNF-alpha10 = 10 
ng/ml TNF-α, TNF-alpha20= 20ng/ml TNF-αand TNF-alpha40= 40 ng/ml TNF-α. Conditions that do not 
share a letter are significantly different from each other (p<0.05).  
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Despite not showing an effect on the protein content, the expression of the seven genes 
tested previously in the dexamethasone and capsaicin experiments were measured for 
each of the three concentrations of TNF-α. While there is a general decline in 
expression with increasing TNF-α concentration, only the reduction in MYH2 
expression induced by the 40ng/ml concentration reached significance (Fig. 12a) 
compared to the untreated control (p=0.042). The expression seen with this 
concentration was not significantly lower than the other three concentrations 
investigated.  
 
TNF-α concentration had no effect on TNNT1 expression (Fig. 12b) and no changes 
were seen with the different concentrations on the expression of MYOD1, MYOG and 
the remodelling genes BNIP3, GABARAPL1 and FBXO32 (Fig. 13a-e)    
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Figure 13. The expression of the transcription factors (a) MYOG and (b) MYOD1as well as (c) BNIP3, 
(d) GABARAPL1 and (e) FBXO32 which are linked to skeletal muscle remodelling, of the cells after 
receiving one of four treatments. DM= untreated control, TNF-alpha10 = 10 ng/ml TNF-α, TNF-
alpha20= 20ng/ml TNF-α and TNF-alpha40= 40 ng/ml TNF-α.  
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Chapter 4: Discussion 
In the present study human skeletal myoblasts were used to asses and validate the use of 
dexamethasone and TNFα as methods to induce skeletal muscle atrophy in this 
commercially available cell line after differentiation into myotubes. The study also 
sought to elucidate the effects of capsaicin and the cellular response to treatments with 
dexamethasone, dexamethasone together with capsaicin, capsaicin alone and TNF-α by 
measuring DNA and protein contents, protein:DNA ratio and gene expression. In 
addition, to also investigate the potential protective effects of capsaicin against 
dexamethasone-induced skeletal muscle atrophy. As Owens et al (2013) found some 
differences in the differentiation capacity and the response to treatments in human 
skeletal muscle cell lines from different vendors, the first aim of this study was 
therefore to characterise the differentiation process in these skeletal muscle cells. From 
the gene expression assessment of MYOD1, MYOG and MYH2 differentiation was 
confirmed in agreement with the findings by Owens et al (2013) and the information 
supplied by Lonza, validating the use of this cell line as a model for investigating 
skeletal muscle cell adaptation.  
 
This study shows that 50μM of dexamethasone is sufficient to induce atrophy in these 
myotubes as treatment significantly reduced the protein:DNA ratio and MYH2 
expression, without inducing any changes in the expression of genes associated with 
protein degradation. 100nM capsaicin when added to the DM caused no toxic effects 
and induced significant increases in the expression of MYH2 and MYOG, as well as 
GABARAPL1. The combined treatment of dexamethasone and capsaicin did not 
display the same level of changes in gene expression as the dexamethasone-only 
43 
 
treatment. This may indicate that capsaicin has the potential to ameliorate some of the 
effects of dexamethasone and somewhat normalize gene expression, brining it closer to 
the levels seen in the untreated control cells. TNF-α treatment with a range of different 
concentrations failed to induce atrophy in these myotubes.  
 
Skeletal muscle mass is maintained through the careful control of protein turnover, the 
balance between the degradation and synthesis of proteins. Protein degradation is 
mediated through two main processes; the ubiquitin-proteasome pathway and 
autophagy. Atrophy is the loss in skeletal muscle mass and decrease in muscle fibre size 
as a result of a disruption in the control of these two processes
1,3,12,15,25
. There are 
several causes for atrophy it can be the result of malnutrition, aging and diseases like 
cancer, AIDS and COPD
7,10,13
. Skeletal muscle mass is in many of these conditions 
directly linked to treatment success, quality of life and mortality. In cancer wasting of 
skeletal muscle is seen in roughly 50% of all cancer patients and it has been associated 
with ~20% of all cancer related deaths
4,7
. The age associated loss of skeletal muscle 
mass, sarcopenia, in turn has been linked to increased risks of falls, frailty and reduced 
quality of life
10
. While the conditions causing atrophy do so through slightly different 
mechanisms, all atrophic conditions ultimately stem from a disruption in the processes 
maintaining skeletal muscle mass
15
.  
 
Skeletal muscle is a responsive tissue capable of adaptation in response to stimuli and 
regeneration when injured. This generation of new skeletal muscle is termed 
myogenesis
64
. Myogenesis allow the skeletal muscle to balance the turnover of skeletal 
muscle cells, and for active renewal to take place. Myogenesis in adult skeletal muscle 
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is dependent on the activation of satellite cells and their differentiation into new 
myotubes and myofibers, and this, is in part, regulated by the expression of myogenic 
regulatory factors (MRFs)
64,65
. The activation of satellite cells by these myogenic 
regulatory factors gives rise to progenitor cells committed to the myogenic program, 
myoblasts, which undergo differentiation to form myotubes. The myogenic factor 5 
(Myf5) and MyoD commits the myoblasts to the myogenic program and starts the 
differentiation process
64
. The expression of MyoD is increased in the beginning of the 
differentiation process, but in the later stages of differentiation this is reduced with a 
coordinated increase in the MFRs myogenin and myogenic regulatory factor 4 (MRF4). 
Myogenin and MRF4 facilitate the fusion of differentiating myoblasts into myotubes 
and terminate the differentiation process 
64–66
. Owens et al (2013) investigated the 
differentiation capacity of four human primary skeletal muscle cell lines and 
characterized the expression of MYOD and MYOG and other markers of cellular 
differentiation, TNNT and MYH2, and found differences both in capacity and 
expression of these markers in different muscle cell lines
63
. Therefore this study first 
sought to characterise the expression of MYOD, MYOG and MYH2 in the skeletal 
muscle cells used. While the expressions of MYOG and MYH2 are in agreement with 
the expression levels observed by Owens et al (2013) significantly increasing on day 3 
after differentiation was induced this was not the case with MYOD. MYOD expression 
was expected to be significantly elevated by day 1 of differentiation and to afterwards 
decrease as expression of MYOG and MYH2 increases. In this study however, there is a 
small, non-significant increase in MYOD expression on day 1 of differentiation. This 
discrepancy with previous literature is likely due to the high variability of the data, 
which is very clear in the data of day 5 (fig.2), and it is probable that this masks some of 
the effects of differentiation. With this small increase in expression of MYOD seen on 
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day 1 taken into account with the elevations of MYOG and MYH2 expression on day 3, 
then expected expression pattern of these MRFs during differentiation were confirmed 
in this skeletal muscle cell culture model.  
 
When the balance in protein turnover is disrupted and the muscle enters a state of 
negative balance as degradation rates exceed the rates of synthesis, atrophy occurs. 
There are two main degradation pathways which both play a role in the maintenance of 
cellular function and development, the UPP and the autophagy pathway and both have 
been shown to be up-regulated during atrophy. UPP targets proteins for degradation 
using a three step pathway where the interaction of an E1-activating enzyme, an E2-
conjugating enzyme and an E3 ligating enzyme tags proteins with chains of poly-
ubiquitin molecules enabling the proteasome to degrade the specific protein 
1,13,27
. The 
autophagic pathway consists of three different mechanisms for the degradation of 
proteins and organelles by the lysosome; microautophagy involves the direct 
engulfment of parts of the cytosol by the lysosome, chaperone-mediated autophagy 
requires the recognition of a specific amino acid sequence by Hsc70 for the 
translocation of the protein into the lysosome to take place, and macroautophagy 
involves the formation of a double membrane vacuole, an autophagosome, containing 
the protein, or organelle which is to be degraded. The autophagosome then fuses with 
the lysosomal membrane, enabling the degradation of the inner membrane of the 
autophagosome and its content by the lysosome
13,14,30
.  
 
Glucocorticoids like dexamethasone have been frequently used to induce atrophy in 
rodents and cell cultures as excessive levels of glucocorticoids in patients suffering 
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from Cushing’s syndrome and in patients receiving glucocorticoid treatments cause 
skeletal muscle atrophy
15,45,46
. Dexamethasone treatments have been shown to reduce 
skeletal muscle mass, myofibre size, mitochondrial content and function in rodents and 
in mouse C2C12, rat L6 cell lines
19,27,38,47–50,67
 and human skeletal muscle cell lines
63
. 
Dexamethasone, and other glucocorticoids, induces atrophy by altering both protein 
breakdown and synthesis. By activating the glucocorticoid receptor and its target genes 
REDD1 and KLF15, protein synthesis via the Akt/mTOR pathway is inhibited and 
degradation is stimulated through the action of KLF15 on FBXO32 and 
FOXO
14,30,31,33,53
. As FOXO-activation is known to drive the up-regulation of the E3 
ligases MuRF1 and FBXO32, and facilitate their translocation into the cytoplasm, this 
increases the degradation of their substrates MyoD, eIF3-f, myosin heavy chain and 
myosin light chain through the UPP
24,26,33
. Dexamethasone also increases the activation 
of the autophagy pathway through the activation of FOXO
50,52
, as FOXO in turn 
governs the expression of LC3, BNIP3 and GABARAPL1 which play a key role in the 
formation of the autophagosome and the targeted degradation of mitochondria
14,30,31
. In 
addition, dexamethasone treatment have also been shown to inhibit both the 
phosphorylation of Akt and Akt protein content in skeletal muscle, and due to its role in 
mTOR signalling and activation, this have direct effects on protein synthesis. In 
addition, mTOR as well as the phosphorylation of the downstream target p70S6K have 
been shown to be inhibited by dexamethasone treatment
1,26,48,50,51,68
. As Akt also 
functions as an inhibitor of FOXO, the dexamethasone blockage of Akt therefore acts 
on FOXO in two ways. The down-regulation of the protein synthesis pathways and the 
up-regulation of protein degradation through both the UPP and the autophagy pathway 
lead to the reduced muscle fibre size, disruption of myotube formation and decrease in 
myotube size seen in dexamethasone-induced atrophy
38,48,49,52
.  
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Previous studies have highlighted differences in the response to dexamethasone 
between cell lines of different species
49
, and some differences between commercially 
available human skeletal muscle cell lines as well
63
. Thus, it was important to firstly 
validate the use of dexamethasone and the 50μM concentration in this line of muscle 
cells. The results of the present study show that dexamethasone treatment did indeed 
induce some of the expected changes in protein turnover and gene expression. The 
addition of dexamethasone to the DM reduced MYH2 expression and greatly reduced 
the protein: DNA ratio in these cells. Expression of TNNT1 differed between the first 
and the second experiment and as this is likely due to the differences in treatment length 
and the stage of differentiation at which the dexamethasone was added, it is impossible 
to draw any conclusions regarding the effect of this treatment on TNNT1 expression. 
Surprisingly, this dexamethasone treatment did not induce any changes in the 
expression of MYOG, BNIP3, GABARAPL1 and FBXO32 contrary to previous 
studies. The treatment also resulted in a large increase of MYOD1 expression, which 
was also somewhat unexpected. MYOD1 has been shown previously to be down-
regulated with dexamethasone treatment and the protein being a substrate for 
FBXO32
24,27
. However protein levels of FBXO32 and MYOD1 were not measured in 
this study and the expression of FBXO32 was unaffected by dexamethasone treatment, 
therefore it is likely that there is an alternative explanation for this increase in MYOD1. 
However, there are some studies that support this finding.  MYOD expression has also 
been shown to increase with dexamethasone treatment in C2C12 myoblast
69
, male rat 
anterior tibialis muscle
70
 but also in the skeletal muscle of chickens
71
. Even more 
interesting to this is the finding by Pessina et al (2010). They found that MYOD 
expression is increased in male and female patients with gastric cancer, but only in the 
early stages of the disease
72
. Together these findings may indicate a cellular response to 
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the atrophy whereby MYOD is part of a regeneration process to counteract the atrophy 
and increased protein degradation. While some of these findings are somewhat different 
from previous research, based on the protein content and protein: DNA ratio data and 
the reduction in MYH2, dexamethasone successfully induced atrophy in these human 
skeletal myoblast, and while no further up-regulation of the ubiquitin-proteasomal or 
autophagic-lysosomal pathways were seen, these are ongoing processes in 
differentiating cells and are likely to still play a vital role in the atrophy response seen in 
the current study.   
 
Ito et al (2013) showed that nNOS regulated overload-induced hypertrophy in mice by 
the production of nitric oxide and peroxynitrite, leading to the activation the TRPV1.  
They did this using synergistic ablation of the tendons to the soleus and gastrocnemius 
muscles to stimulate overload-induced hypertrophy of the plantaris muscles. The 
resulting increase in [Ca
2+
]i by the activation of TRPV1, phosphorylates mTOR and the 
down-stream targets p70S6K and S6 without the activation of Akt
61
. Interestingly these 
studies also showed that dietary supplementation of the TRPV1 agonist capsaicin 
resulted in similar phosphorylation patterns to when TRPV1 was stimulated by nitric 
oxide and peroxynitrite, in addition mice receiving only the capsaicin supplement 
displayed a hypertrophy phenotype compared to the control group
61
. The follow-up 
experiment to this found that dietary supplementation of capsaicin prevented some of 
the muscle loss normally seen during denervation and hindlimb suspension in mice 
through the activation of TRPV1 and its subsequent activation of the mTOR pathway. 
They proposed capsaicin to be a mimic of resistance exercise as the phosphorylation 
pattern induced by capsaicin supplementation in these mice highly resembled the 
pattern induced by their model of mechanical overload
62
. As resistance exercise is one 
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of the few successful ways to stimulate mTOR activation and to induce hypertrophy
35
 
the suggested potential of capsaicin to mimic these responses and to prevent atrophy 
offers great possibilities.  
 
As these studies were performed in mice we therefore wanted to investigate the effects 
of capsaicin on human muscle and therefore administered capsaicin in isolation as well 
as in combination with atrophy-inducing dexamethasone to myotubes differentiated 
from a human skeletal muscle cell line. When 100nM capsaicin was administered to the 
myotubes in isolation there were no changes in either DNA content, protein content or 
protein:DNA ratio, and it is therefore concluded that capsaicin at this concentration has 
no toxic effects. From this observation it is also unlikely that capsaicin induces any 
large-scale effects on protein turnover. However the addition of capsaicin to the 
medium resulted in a large increase in the expression of MYH2. This would be 
consistent with the increases in muscle mass found by Ito et al (2013). Thus, if capsaicin 
truly were a resistance exercise mimic then its action would lead to larger fibres and an 
increased need for myosin heavy chain proteins
35,61,62
. However increased 
concentrations of capsaicin offered no additional effect in our cells. The current study, 
and the Ito studies did not measure myosin heavy chain protein levels, neither was the 
levels of the ubiquitin ligase MuRF1 which is known to degrade myosin heavy chain, 
measured. Therefore to fully understand the process and the implication of the increased 
MYH2 expression, these measures would be necessary. Capsaicin treatment also 
increased MYOG and GABARAPL1 expression, indicating an increased rate of 
differentiation and fusion into myotubes as the transcription factor myogenin is 
expressed later in the differentiation process and known to govern the termination of 
differentiation and the fusion of myocytes into myotubes
64,73,74
. GABARAPL1 on the 
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other hand is an autophagy gene, and the protein is present in many locations of the 
muscle cell
75
. GABARAPL1 has been associated with the formation and maturation of 
autophagosomes and it is likely that the increased expression of GABARAPL1 
potentiates the fusion of myocytes, facilitating the formation of myotubes by its 
presence in the cytoplasm and its autophagic role
75,76
. This isolated capsaicin treatment 
did not induce any other changes in the expression of the genes investigated linked to 
cellular remodelling, BNIP3 and FBXO32.  
 
When 100nM capsaicin was added to the medium in combination with dexamethasone 
both the protein content and the protein:DNA ratio were dramatically increased above 
the levels seen when dexamethasone was used in isolation. Of the four concentrations of 
capsaicin that were investigated, this concentration was the only one that reached a 
significant elevation above the protein content and protein:DNA ratio of the 
dexamethasone-only treatment. Changes in gene expression of the myotubes were 
therefore assess using 100nM capsaicin in combination with 50μM dexamethasone and 
compared to dexamethasone-only and untreated control. Interestingly, the addition of 
capsaicin to the dexamethasone does not induce significantly different results from what 
was seen using dexamethasone alone. However, while statistical significance were not 
reached capsaicin seem to somewhat counteract the dexamethasone-induced effects, 
bringing gene expression closer to the levels seen in the control cells. This is 
particularly clear with the expression of MYOD1, where dexamethasone-only is 
significantly elevated above the expression in control cells. The combined treatment on 
the other hand is not significantly higher than that of untreated cells, nor is it 
significantly lower than the dexamethasone-only treated cells. The expression of 
MYOG also shows this trend.  While none of the treatments are significantly different 
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from one another, the expression seen with dexamethasone treatment is halved 
compared to the control levels, and then brought up to the same level as control with the 
combined treatment. The increased protein content, protein: DNA ratio and the 
normalisation of the gene expression in genes altered with dexamethasone-only 
treatment might be the result of stimulated protein synthesis through the activation of 
mTOR and its targets by the increase in intracellular calcium concentration through the 
TRPV1. These results thus indicate a potential for capsaicin to protect against 
dexamethasone-induced changes in gene expression and the resulting atrophy. 
However, this experiment needs to be repeated to confirm these findings as the data set 
is limited by a high sample variance which could account for some of the discrepancies 
seen in the dexamethasone data when comparing the gene expression between the first 
experiment in section 3.3 and to the second experiment in section 3.4. Being a pilot 
study there were also direct differences in methodology between these two experiments.  
The seeding density, treatment length and the time point at which the respective 
treatments were added to the cell culture differed slightly between them and this may 
well have caused some of the discrepancies seen here. This is the first study to our 
knowledge to assess the gene expression changes that take place in human skeletal 
myotubes when treated with dexamethasone, capsaicin or a combination of the two. As 
protein levels related to each gene were not measured and the Akt/mTOR pathway was 
not further investigated, the mechanisms behind this proposed protective effect by 
capsaicin on dexamethasone-induced atrophy remain unclear. The findings of the 
current study highlights a potential effect of capsaicin on muscle function and the 
response to dexamethasone-induced atrophy, and show the need for future work.  
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In addition to investigating the effects of dexamethasone and capsaicin this current 
study also sought to validate the atrophy-inducing effects of TNFα in this cell line as the 
role of TNFα and other pro-inflammatory cytokines in the skeletal muscle atrophy seen 
in relation to cancer have been greatly disputed
13,58,77,78
. Addition of 20ng/ml TNFα to 
the differentiation medium was shown to inhibit differentiation and myotube formation 
in human primary cells, and it has been shown to induce atrophy through the NF-KB 
pathway and the activation of p38 MAP kinase
59,60
. The activation of both NF-KB and 
p38 MAPK and their translocation to the nucleus results in the increased expression of 
both MuRF1 and FBXO32 as well and stimulates protein breakdown and decrease 
protein synthesis through the FOXO mediated atrogens
2,13,56,58–60,79,80
. In addition, TNFα 
treatment has also been proposed to induce skeletal muscle atrophy through the 
increased levels of ceramides
58,80. Treatment with 15ng/ml TNFα was found to reduce 
surface area of C2C12 and L6 myotubes, as well as result in decreased protein 
synthesis, increased protein degradation by the up-regulated activation of FOXO and  
expression of FBXO32 but without inducing any change in MuRF1
58
. The 12-hour 
TNFα treatment, also lead to decreases in the protein contents of myosin heavy chain 
and eIF3-f. These TNFα-induced atrophy-responses were inhibited when ceramide-
synthesis inhibitors were administered, indicating the role of ceramide synthesis in 
TNFα-induced atrophy. In the current study myotubes were treated with 10, 20 and 40 
ng/ml TNFα and DNA content, protein content and protein: DNA ratio as well as gene 
expression were measured. Contrary to some of the previous studies these 
concentrations failed to induce atrophy in these human skeletal myotubes and resulted 
in no changes in protein content, protein: DNA ratio or the expression of TNNT1, 
MYOD1, BNIP3, GABARAPL1 and FBXO32. The 10ng/ml TNFα did however result 
in a significant decrease in total DNA content, but with no change to the protein:DNA 
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ratio. In agreement with the findings of De Larichaudy et al (2013) the myotubes did 
however express significantly lower levels of MYH2 when treated with 40ng/ml TNFα, 
compared to the untreated controls. This concentration is much higher than that used by 
De Larichaudy et al (2013) and while their results showed no increase in MuRF1 
expression, it is possible that this TNFα treatment affected MuRF1 ligase activity but 
MuRF1 expression was not measured. Based on these results and the lack of atrophy 
seen TNFα treatment cannot be recommended as a method to induce atrophy in these 
human skeletal myotubes. It is however plausible that the results seen in this study is 
due to the use of the wrong concentrations, although concentrations of 15-20ng/ml 
TNFα have been used previously in both murine and human primary cell lines. The 
serum levels of TNFα in patients with gastric cancer and colorectal cancer have been 
shown to be within a much lower concentration, 3.7±7.3 pg/ml
57
 and 22.3±13.9 pg/ml 
respectively
81. Although the levels of circulating TNFα may not accurately reflect the 
levels of the cytokine within the muscle
49,79
 the lower levels seen in cancer patients 
might be closer to the optimal atrophy-inducing concentration of TNFα.  Thus 
optimization experiments to elucidate the adequate concentration of TNFα to induce 
atrophy in this cell line needs to be conducted and the processes involved further 
investigated.  
 
Atrophy of skeletal muscle have been shown to result in the targeted destruction of 
mitochondria through macroautophagy, mitophagy,
13,19
 and several rodent models of 
cancer cachexia have found an impairment of mitochondrial function and decrease in 
mitochondrial numbers, as well as decreased expression of peroxisome proliferator-
activated receptor gamma, co-activator 1 alpha (PGC-1α) in the skeletal muscle of 
tumour-bearing mice
6,82
. Up-regulation of mitochondrial E3 ubiquitin protein ligase 1 
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(Mul1) has been shown to decrease mitochondrial function and to promote the 
fragmentation and destruction of these organelles during muscle atrophy induced with 
myostatin and with dexamethasone but also during denervation and starvation
19
. With 
the knockdown of Mul1 expression Lokireddy et al (2012) found that the mitochondrial 
fragmentation and degradation seen in control cells, as a result of these treatments with 
myostatin or dexamethasone, were inhibited in C2C12 myotubes and instead 
mitochondrial fusion was promoted. The study showed that Mul1 acts as an E3 ligase 
for the mitochondrial fusion protein Mfn2, which regulates mitochondrial fusion and 
morphology
83
, and Mul1 was proposed as a key regulator of the mitophagy seen with 
atrophy
19
. As Mul1 is under the control of FOXO, like BNIP3, MuRF1 and FBXO32, 
the activation of this transcription factor seem to be the key regulator for many of the 
effects seen in skeletal muscle atrophy. The potential of capsaicin as a mediator of 
muscle wasting is even more intriguing when the disruption of mitochondrial function 
during atrophy is considered, as it was recently shown that the capsaicin-mediated 
activation of TRPV1 up-regulated PGC-1α in mice84. This research showed that TRPV1 
was present in both mice and the C2C12 mouse cell lines, and could be activated by 
capsaicin. The elevation of [Ca
2+
]i through capsaicin-induced activation of TRPV1 in 
C2C12 myotubes led to an increase in the expression of PGC-1α, enhanced 
mitochondrial biogenesis and ATP production. In mice this TRPV1 activation also 
induced up-regulation of PGC-1α expression, and in addition led to an increase in 
mitochondrial number and skeletal muscle remodelling. This remodelling was 
confirmed with the increased percentage of type I oxidative muscle fibres, the increased 
oxidative respiratory and endurance capacity seen in these mice compared to controls
84
. 
Taken together the study by Luo et al (2012) therefore provides another role for 
capsaicin-induced TRPV1 activation in skeletal muscle maintenance and function, but 
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also highlights the need for further study. As the current study successfully achieved the 
staining of mitochondria in the human myotubes using MitoTracker Green, measuring 
the effects of capsaicin and dexamethasone on mitochondrial content using this dye 
could be a next step to elucidate the effects of capsaicin on skeletal muscle function and 
its role in the prevention of dexamethasone-induced atrophy.  
 
Menconi et al (2008) highlighted differences in the response to dexamethasone 
treatment in L6 and C2C12 myotubes, and Owens et al (2013), in addition, 
demonstrated differences in differentiation capacity and gene expression between four 
human skeletal muscle cell lines. Some of these differences can be attributed to the 
different mammal species, but as in the case of the study by Owens et al (2013) donor 
characteristics are likely to influence the characteristics of the cells. The profuse 
variability between people most likely play a role in cellular responses, with factors 
such as gender, age, ethnicity, health and lifestyle being able to influence results. The 
current study was conducted using one line of human skeletal muscle myotubes, i.e cells 
from one donor (n=1). Therefore to increase the reliability of these findings and to 
reduce some of the variability seen in these data, the study should be repeated using 
cells from more than one donor, taking care to minimise the variability in donor 
characteristics when doing so. As the current study was designed for pilot data 
collection and method development, there were some inconsistencies in the 
methodology used for the different experiments, with variations in seeding densities, 
treatment length and the time point at which the treatments were added to the 
differentiation medium. Thus future work should also try to limit these inconsistencies. 
One major limitation to the current study was that role of the TRPV1 was not 
investigated. The use of a TRPV1 antagonist, for example capsazepine, would greatly 
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increase the understanding the action of capsaicin and elucidate the mechanisms 
involved in the cellular response to capsaicin. In summary future work would include; 
repeating these experiments under standardised conditions, further investigation of the 
optimal concentration for TNFα to induce atrophy in these myotubes and to explore the 
effect of capsaicin in this setting, investigation of the effects of lower concentrations of 
capsaicin in dexamethasone-induced atrophy, and the effect of pre-treating of capsaicin 
before the induction of atrophy; as well as measuring protein levels and activation of the 
E3 ligases MuRF1, FBXO32 and further investigate the effects of capsaicin on protein 
synthesis.  
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Chapter 5: Conclusion 
In conclusion the findings of this study support previous research and show that this line 
of skeletal muscle myotubes is a useful model for measuring dexamethasone-induced 
atrophy, and changes in gene expression, DNA, protein and protein:DNA ratio levels 
from the dexamethasone treatment. In addition, capsaicin influences the expression of 
myosin heavy chain and seems to moderate dexamethasone-induced atrophy in these 
human myotubes. TNF-α at the concentrations used in this study failed to induce 
atrophy in this cell line and had no overall effects on DNA and protein content, 
protein:DNA ratio nor did it induce any significant changes in the expression of the 
genes measured. The current study points toward a potential for capsaicin to normalise 
gene expression during dexamethasone-induced atrophy in this line of human myotubes, 
however to fully understand the mechanisms and processes involved, and its role on 
protein turnover further research is needed.     
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